German company BioNTech, Pfizer’s partner in the manufacture of vaccines against Covid-19, said the two companies will start human trials of new immunizations that protect against a wide variety of coronavirus mutations in the second half of the year.
Experimental work on injections that goes beyond the current approach includes T-cell augmentation injections, designed primarily to protect against serious illness if the virus becomes more dangerous, and pan-coronavirus vaccines that protect against the broader family of viruses and their mutations.
The two partners, makers of the most widely used Covid-19 vaccine in the western world, are currently in discussions with regulators with improved versions of their established vaccine to better protect against the Ômicron variant and its substrains.
Last Saturday (25), Pfizer released promising data on the adapted version of the Covid-19 vaccine specific to the Ômicron variant.
According to the drugmaker, data from the phase 2 and 3 study showed that a booster dose of both adapted vaccine candidates provoked a substantially greater immune response against BA.1 from Omicron BA.1 compared to the current vaccine.
Robust immune response was observed at two dose levels of 30 and 60 micrograms.
*With information from Lucas Rocha, from CNN
Source: CNN Brasil
